Back to Search Start Over

Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer

Authors :
Simons, Janine M
van Nijnatten, Thiemo J A
van der Pol, Carmen C
van Diest, Paul J
Jager, Agnes
van Klaveren, David
Kam, Boen L R
Lobbes, Marc B I
de Boer, Maaike
Verhoef, Cees
Sars, Paul R A
Heijmans, Harald J
van Haaren, Els R M
Vles, Wouter J
Contant, Caroline M E
Menke-Pluijmers, Marian B E
Smit, Léonie H M
Kelder, Wendy
Boskamp, Marike
Koppert, Linetta B
Luiten, Ernest J T
Smidt, Marjolein L
Simons, Janine M
van Nijnatten, Thiemo J A
van der Pol, Carmen C
van Diest, Paul J
Jager, Agnes
van Klaveren, David
Kam, Boen L R
Lobbes, Marc B I
de Boer, Maaike
Verhoef, Cees
Sars, Paul R A
Heijmans, Harald J
van Haaren, Els R M
Vles, Wouter J
Contant, Caroline M E
Menke-Pluijmers, Marian B E
Smit, Léonie H M
Kelder, Wendy
Boskamp, Marike
Koppert, Linetta B
Luiten, Ernest J T
Smidt, Marjolein L
Source :
JAMA Surgery vol.157 (2022) nr.11 p.991-999 [ISSN 2168-6254]
Publication Year :
2022

Abstract

Importance: Several less-invasive staging procedures have been proposed to replace axillary lymph node dissection (ALND) after neoadjuvant chemotherapy (NAC) in patients with initially clinically node-positive (cN+) breast cancer, but these procedures may fail to detect residual disease. Owing to the lack of high-level evidence, it is not yet clear which procedure is most optimal to replace ALND.Objective: To determine the diagnostic accuracy of radioactive iodine seed placement in the axilla with sentinel lymph node biopsy (RISAS), a targeted axillary dissection procedure.Design, Setting, and Participants: This was a prospective, multicenter, noninferiority, diagnostic accuracy trial conducted from March 1, 2017, to December 31, 2019. Patients were included within 14 institutions (general, teaching, and academic) throughout the Netherlands. Patients with breast cancer clinical tumor categories 1 through 4 (cT1-4; tumor diameter <2 cm and up to >5 cm or extension to the chest wall or skin) and pathologically proven positive axillary lymph nodes (ie, clinical node categories cN1, metastases to movable ipsilateral level I and/or level II axillary nodes; cN2, metastases to fixed or matted ipsilateral level I and/or level II axillary nodes; cN3b, metastases to ipsilateral level I and/or level II axillary nodes with metastases to internal mammary nodes) who were treated with NAC were eligible for inclusion. Data were analyzed from July 2020 to December 2021.Intervention: Pre-NAC, the marking of a pathologically confirmed positive axillary lymph node with radioactive iodine seed (MARI) procedure, was performed and after NAC, sentinel lymph node biopsy (SLNB) combined with excision of the marked lymph node (ie, RISAS procedure) was performed, followed by ALND.Main Outcomes and Measures: The identification rate, false-negative rate (FNR), and negative predictive value (NPV) were calculated for all 3 procedures: RISAS, SLNB, and MARI. The

Details

Database :
OAIster
Journal :
JAMA Surgery vol.157 (2022) nr.11 p.991-999 [ISSN 2168-6254]
Notes :
DOI: 10.1001/jamasurg.2022.3907, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1376707041
Document Type :
Electronic Resource